Profitability ratios measure the company ability to generate profitable sales from its resources (assets).
Paying user area
Try for free
Illumina Inc. pages available for free this week:
- Common-Size Income Statement
- Common-Size Balance Sheet: Liabilities and Stockholders’ Equity
- Analysis of Short-term (Operating) Activity Ratios
- Analysis of Long-term (Investment) Activity Ratios
- Analysis of Geographic Areas
- Enterprise Value to EBITDA (EV/EBITDA)
- Price to FCFE (P/FCFE)
- Operating Profit Margin since 2005
- Analysis of Revenues
- Aggregate Accruals
The data is hidden behind: . Unhide it.
Get full access to the entire website from $10.42/mo, or
get 1-month access to Illumina Inc. for $22.49.
This is a one-time payment. There is no automatic renewal.
We accept:
Profitability Ratios (Summary)
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
The financial performance indicators reflect varying trends across the observed periods.
- Gross profit margin
- The gross profit margin exhibited a generally increasing trajectory from early 2017 through early 2020, moving from approximately 67.53% to a peak near 70.36%. Following this peak, a moderate decline occurred through 2021, with values fluctuating between 67.61% and 69.3%. This trend suggests stable and strong control over production and direct costs, though with some slight margin contraction in the later periods.
- Operating profit margin
- The operating profit margin showed improvement from around 21.35% in April 2017 to a peak exceeding 28% in late 2018 and 2019. Subsequently, a declining pattern emerged starting in late 2019, with margins reducing sharply in 2020 and 2021, culminating in negative territory (-0.75%) by October 2021. This notable decrease indicates increased operating expenses or other operational challenges significantly impacting profitability.
- Net profit margin
- Net profit margin trends demonstrate initial stability in the range of approximately 26% to 30% during 2017, followed by a decrease to values between 19% and 28% throughout 2018 and 2019. The margin further declined in 2020, stabilizing near 20%, with a mild recovery noted into 2021 reaching just above 21% by the last period. This fluctuation illustrates variations in overall profitability, affected by both core operations and external factors such as tax and interest expenses.
- Return on equity (ROE)
- ROE showed a downward trend from a high of about 29% in early 2017 to levels near 21% by the end of 2019. A more pronounced decline is observed during 2020 and 2021, dropping to single digits (8.55%) by late 2021. This suggests a reduced capacity to generate profits from shareholders' equity, possibly reflecting challenges in net income generation or increased equity base without proportional profit growth.
- Return on assets (ROA)
- Return on assets tracked a diminishing path from approximately 16.1% in early 2017 to around 13.7% by the end of 2019, followed by further decline throughout 2020 and 2021, reaching a low near 6% by late 2021. The consistent downward tendency highlights decreasing efficiency in utilizing assets to generate earnings.
In summary, while the company maintained a robust gross profit margin suggesting effective cost management in production, profitability at the operating and net levels has faced significant pressures since 2019. This is coupled with declining returns on equity and assets, signaling challenges in sustaining profitability and asset utilization efficiency over time.
Return on Sales
Return on Investment
Gross Profit Margin
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Gross profit | |||||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Gross profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Gross Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q3 2021 Calculation
Gross profit margin = 100
× (Gross profitQ3 2021
+ Gross profitQ2 2021
+ Gross profitQ1 2021
+ Gross profitQ4 2020)
÷ (RevenueQ3 2021
+ RevenueQ2 2021
+ RevenueQ1 2021
+ RevenueQ4 2020)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
The analysis of the financial data over the specified quarters reveals several notable trends concerning gross profit, revenue, and gross profit margin.
- Gross Profit
- The gross profit exhibited an overall upward trajectory from early 2017 through late 2021, beginning at $368 million and reaching peaks above $800 million in the latter quarters of 2021. Notable fluctuations are observed around mid-2020, where gross profit declined significantly to $428 million, followed by a recovery toward the end of 2020 and strong growth in 2021. This dip may indicate temporary operational challenges or market conditions impacting cost of goods sold or pricing power during that period.
- Revenue
- Revenue followed a broadly similar pattern, increasing steadily from $598 million in April 2017 to surpass $1 billion by October 2021. A marked decrease in revenue occurred around the first half of 2020, aligning with the gross profit decline. This suggests that external factors might have influenced sales volume or pricing during that interval. The recovery after mid-2020 was robust, with revenues reaching record highs in 2021.
- Gross Profit Margin
- The gross profit margin remained relatively stable and strong throughout the period, fluctuating between approximately 65.7% and 70.4%. The margin slightly improved starting late 2017, maintaining a high 69-70% range during most of 2018 and 2019. The margin peaked near mid-2020 despite the drop in gross profit and revenue, indicating possible cost efficiencies or improved pricing strategies in response to the revenue downturn. Toward the end of 2021, margins slightly decreased but still reflected healthy profitability levels around 69%.
In summary, the financial performance illustrates consistent growth in revenue and gross profit over the long term, punctuated by a temporary contraction during early to mid-2020. The gross profit margin remained strong and resilient, suggesting effective cost management even during periods of revenue pressure. The rebound in 2021 demonstrates a recovery in sales and profitability, highlighting overall financial resilience and operational effectiveness.
Operating Profit Margin
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Income (loss) from operations | |||||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Operating profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Operating Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q3 2021 Calculation
Operating profit margin = 100
× (Income (loss) from operationsQ3 2021
+ Income (loss) from operationsQ2 2021
+ Income (loss) from operationsQ1 2021
+ Income (loss) from operationsQ4 2020)
÷ (RevenueQ3 2021
+ RevenueQ2 2021
+ RevenueQ1 2021
+ RevenueQ4 2020)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Operating Income Trends
- The operating income exhibited a general upward trend from April 2017 through September 2019, peaking at 308 million USD in the third quarter of 2019. This was followed by a decline starting at the end of 2019, with operating income decreasing significantly in 2020 and 2021, ultimately reaching a negative 545 million USD by October 2021. This indicates a substantial deterioration in operational profitability towards the end of the period analyzed.
- Revenue Trends
- Revenue showed a consistent increase from April 2017 through the fourth quarter of 2019, rising from 598 million USD to a peak of 952 million USD. A sharp decline is observed in the first half of 2020, falling to 633 million USD, likely reflecting external challenges or disruptions. However, revenue rebounded strongly from mid-2020, reaching a high of 1126 million USD by the third quarter of 2021 before slightly declining to 1108 million USD by the last available quarter.
- Operating Profit Margin Dynamics
- The operating profit margin followed a pattern similar to operating income, increasing steadily from a low of 20.01% in October 2017 to a peak of approximately 28% in late 2018 and 2019. Margins remained relatively stable and high through 2019 but began to decline sharply in 2020, correlating with the drop in revenue and operating income. By the end of 2020 and into 2021, margins had fallen to the mid-to-high teens percentage range, ultimately turning slightly negative (-0.75%) in October 2021, indicating that operating expenses began to exceed revenue generating capacity during that period.
- Overall Insights
- The financial data demonstrates that the company experienced strong growth in both revenue and operating profitability until late 2019, followed by a period of financial stress beginning in 2020. Despite recovery in revenue post mid-2020, operating profitability continued to decline, which may suggest increasing costs or other operational challenges. The negative operating income and margin in the latest quarter are particularly notable, signaling a critical need for operational and financial review.
Net Profit Margin
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net income attributable to Illumina stockholders | |||||||||||||||||||||||||
| Revenue | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| Net profit margin1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| Net Profit Margin, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q3 2021 Calculation
Net profit margin = 100
× (Net income attributable to Illumina stockholdersQ3 2021
+ Net income attributable to Illumina stockholdersQ2 2021
+ Net income attributable to Illumina stockholdersQ1 2021
+ Net income attributable to Illumina stockholdersQ4 2020)
÷ (RevenueQ3 2021
+ RevenueQ2 2021
+ RevenueQ1 2021
+ RevenueQ4 2020)
= 100 × ( + + + )
÷ ( + + + )
=
2 Click competitor name to see calculations.
- Net Income Attributable to Stockholders
- The net income shows a fluctuating trend over the periods analyzed, with notable volatility in certain quarters. Initially, net income was strong, peaking at 367 million USD, then declining sharply in the middle of 2017, reaching lows around 68 million USD in December 2017. After this period of fluctuation, net income generally recovers with some inconsistency, especially in 2020 where it dropped significantly to as low as 47 million USD before improving again towards the end of the data series. The most recent quarters show a positive trend, with net income rising to 317 million USD, indicating a recovery and potentially improved profitability.
- Revenue
- Revenue consistently increased from early 2017 through 2019, growing from 598 million USD to a peak of 952 million USD by the end of 2019. However, a notable decline occurs in early 2020, dropping to 633 million USD, which may reflect external disruptions or operational challenges. Following this decline, revenue rebounds strongly in 2021, reaching over 1 billion USD in multiple quarters, peaking at 1,126 million USD, demonstrating robust sales growth and recovery.
- Net Profit Margin
- The net profit margin shows a downward trend from early 2017 to 2018, starting above 30% and declining to around 19-21% during 2018 and 2019. Despite this decline, margins stabilize in a range close to 20-28% through much of the period after 2018. In 2020, margins again dip to the lower 20% range but recover slightly by late 2021, finishing around 21%. The decline from over 30% to around 20% suggests increasing costs or pricing pressures impacting profitability, albeit with some recovery in recent quarters.
- Overall Observations
- The data reflects significant fluctuations in profitability metrics despite relatively steady revenue growth until the disruption in 2020. The dip in both revenue and net income in 2020 suggests an adverse event or market condition influencing performance. The following recovery in revenue and net income in 2021 is a positive indicator of resilience and operational recovery. The reduction in net profit margin over the observed period, however, indicates increasing cost challenges or changes in business dynamics affecting profitability levels, although margins appear to stabilize toward the end of the timeframe.
Return on Equity (ROE)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net income attributable to Illumina stockholders | |||||||||||||||||||||||||
| Total Illumina stockholders’ equity | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROE1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROE, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q3 2021 Calculation
ROE = 100
× (Net income attributable to Illumina stockholdersQ3 2021
+ Net income attributable to Illumina stockholdersQ2 2021
+ Net income attributable to Illumina stockholdersQ1 2021
+ Net income attributable to Illumina stockholdersQ4 2020)
÷ Total Illumina stockholders’ equity
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
The financial analysis reveals several noteworthy trends in the quarterly performance over the observed periods.
- Net Income Attributable to Illumina Stockholders
- Net income demonstrated significant volatility throughout the periods. Initial figures reached 367 million USD but subsequently experienced fluctuations, including noticeable declines to lows such as 47 million USD in mid-2020. A generally upward trajectory is visible toward the end of the timeline, peaking at 317 million USD by late 2021. These variations suggest cyclical profitability possibly influenced by external market factors or internal operational adjustments.
- Total Illumina Stockholders’ Equity
- Stockholders’ equity exhibited a consistent upward trend across the quarters, increasing from approximately 2,551 million USD to 10,593 million USD by the final reported quarter. The steady rise indicates sustained capital growth and accumulation of retained earnings, reflecting ongoing investments and financial strengthening of the company’s equity base over time.
- Return on Equity (ROE)
- ROE showed a declining trend overall, starting at a high of 29.01% and decreasing to 8.55% by the last quarter. Notably, reductions in ROE coincide with the periods where net income was comparatively lower, despite the increasing equity base. This decline suggests that the company's profitability relative to its equity has diminished, potentially due to slower earnings growth or increased equity diluting returns.
In summary, while equity has grown significantly, net income has been inconsistent, and the efficiency in generating profit from equity—indicated by ROE—has declined notably. This combination signals a need to investigate factors impacting profit generation and consider measures to enhance return metrics amidst the expanding equity base.
Return on Assets (ROA)
| Oct 3, 2021 | Jul 4, 2021 | Apr 4, 2021 | Dec 31, 2020 | Sep 27, 2020 | Jun 28, 2020 | Mar 29, 2020 | Dec 29, 2019 | Sep 29, 2019 | Jun 30, 2019 | Mar 31, 2019 | Dec 30, 2018 | Sep 30, 2018 | Jul 1, 2018 | Apr 1, 2018 | Dec 31, 2017 | Oct 1, 2017 | Jul 2, 2017 | Apr 2, 2017 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Net income attributable to Illumina stockholders | |||||||||||||||||||||||||
| Total assets | |||||||||||||||||||||||||
| Profitability Ratio | |||||||||||||||||||||||||
| ROA1 | |||||||||||||||||||||||||
| Benchmarks | |||||||||||||||||||||||||
| ROA, Competitors2 | |||||||||||||||||||||||||
| AbbVie Inc. | |||||||||||||||||||||||||
| Amgen Inc. | |||||||||||||||||||||||||
| Bristol-Myers Squibb Co. | |||||||||||||||||||||||||
| Danaher Corp. | |||||||||||||||||||||||||
| Eli Lilly & Co. | |||||||||||||||||||||||||
| Gilead Sciences Inc. | |||||||||||||||||||||||||
| Johnson & Johnson | |||||||||||||||||||||||||
| Merck & Co. Inc. | |||||||||||||||||||||||||
| Pfizer Inc. | |||||||||||||||||||||||||
| Regeneron Pharmaceuticals Inc. | |||||||||||||||||||||||||
| Thermo Fisher Scientific Inc. | |||||||||||||||||||||||||
| Vertex Pharmaceuticals Inc. | |||||||||||||||||||||||||
Based on: 10-Q (reporting date: 2021-10-03), 10-Q (reporting date: 2021-07-04), 10-Q (reporting date: 2021-04-04), 10-K (reporting date: 2020-12-31), 10-Q (reporting date: 2020-09-27), 10-Q (reporting date: 2020-06-28), 10-Q (reporting date: 2020-03-29), 10-K (reporting date: 2019-12-29), 10-Q (reporting date: 2019-09-29), 10-Q (reporting date: 2019-06-30), 10-Q (reporting date: 2019-03-31), 10-K (reporting date: 2018-12-30), 10-Q (reporting date: 2018-09-30), 10-Q (reporting date: 2018-07-01), 10-Q (reporting date: 2018-04-01), 10-K (reporting date: 2017-12-31), 10-Q (reporting date: 2017-10-01), 10-Q (reporting date: 2017-07-02), 10-Q (reporting date: 2017-04-02).
1 Q3 2021 Calculation
ROA = 100
× (Net income attributable to Illumina stockholdersQ3 2021
+ Net income attributable to Illumina stockholdersQ2 2021
+ Net income attributable to Illumina stockholdersQ1 2021
+ Net income attributable to Illumina stockholdersQ4 2020)
÷ Total assets
= 100 × ( + + + )
÷ =
2 Click competitor name to see calculations.
- Net Income Trends
- Net income attributable to stockholders shows notable volatility over the observed periods. Initially, net income was strong at 367 million US dollars in early 2017 but declined sharply in mid-2017 before recovering modestly by the end of 2018. Beginning in 2019, net income experienced fluctuations with a general upward tendency marked by peaks in Q2 2019 (296 million) and Q4 2021 (317 million). However, notable dips occurred in mid-2020, reflecting possible operational or market challenges during that time.
- Total Assets Growth
- Total assets display a consistent upward trajectory, indicating expanding resource base or investments. Starting at approximately 4.6 billion US dollars in early 2017, total assets increased steadily until late 2019, where they hovered around 7.3 billion. A slight plateau is evident through 2020, but assets surged dramatically in late 2021, reaching over 15 billion US dollars, suggesting significant acquisitions, capital investments, or other asset growth events during that period.
- Return on Assets (ROA) Behavior
- Return on assets shows a declining trend throughout the period. Early observations indicate a high ROA above 15% in 2017, which gradually decreases to below 7% by late 2021. This decline suggests diminishing efficiency in generating income from assets, which may be attributed to rapid asset growth outpacing net income increases or changes in profitability dynamics.
- Interrelationships and Insights
- The data points to a scenario where asset base expansion is not matched proportionally by net income growth, as evidenced by the decreasing ROA. Despite some recovery in net income figures, especially towards the end of the examined timeframe, the substantial increase in total assets, particularly by late 2021, may have diluted overall profitability efficiency. The volatility in net income, coupled with steady asset accumulation, calls for further investigation into the composition of assets and the strategic initiatives behind such growth to assess longer-term financial sustainability and operational efficiency.